An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Mt Sinai Medical Center - NY, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York

Local Institution - 506, Hamburg

Levine Cancer Institute, Charlotte

Emory University School of Medicine, Atlanta

Clinica Universidad de Navarra, Pamplona

Moffitt Cancer Center, Tampa

Local Institution - 704, Salamanca

Tennessee Oncology PLLC, Nashville

Local Institution - 603, Bologna

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee

Washington University, St Louis

University Of Texas Southwestern Medical Center, Dallas

MD Anderson Cancer Center The University of Texas, Houston

Mayo Clinic in Arizona - Scottsdale, Scottsdale

Local Institution - 404, Poitiers

University Of California San Francisco Medical Center, San Francisco

Local Institution - 505, Würzburg

Swedish Cancer Inst, Seattle

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston

University Of Nebraska, Omaha

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Kings College Hospital NHS Foundation Trust, London